Send Orders for Reprints to
[email protected] Current Vascular Pharmacology, 2017, 15, 000-000
1
RESEARCH ARTICLE
Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma Silvia Lai1,*, Alessio Molfino1, Patrizia Seminara2, Flavia Longo2, Georgie Innico3, Bettina Coppola4, Daniela Mastroluca5, Alessandro Galani6, Mira Dimko7, Paola Aceto8 and Carlo Lai9 Study Group on Geriatric Nephrology of the Italian Society of Nephrology (SIN); 1Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy; 2Medical Oncology Department, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy; 3Department of Medicine DIMED, School of Specialization in Nephrology, University of Padova, Padova, Italy; 4Dialysis Unit, San Giovanni Evangelista Hospital, Tivoli, Italy; 5Nephrology and Dialysis Unit, ICOT Hospital, Latina, Sapienza University of Rome, Italy; 6Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 7Department of Internal Medicine, Clinical Institute San Rocco, Brescia, Italy; 8 Department of Anaesthesia and Intensive care, Catholic University of Sacred Heart Rome, Italy; 9Department of Dynamic and Clinic Psychology, Sapienza University of Rome, Rome, Italy Abstract: Background: Sunitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF), is approved for first and second line treatment of advanced renal cell carcinoma (RCC). Knowledge on the effects of sunitinib on cardiovascular (CV) risk and renal damage is limited. Aim: To evaluate possible renal and CV damage in patients with RCC treated with sunitinib.
ARTICLE HISTORY Received: January 08, 2017 Revised: May 28, 2017 Accepted: May 28, 2017 DOI: 10.2174/1570161115666170621073715
Materials and Methods: Patients with metastatic RCC treated with sunitinib were enrolled. This population was evaluated before starting treatment (T0) and after 3 months (T1). Laboratory and instrumental parameters, including interventricular septum (IVS) and left ventricular mass index (LVMI) were recorded before and after treatment. Results: Thirty-two patients (13 female, 19 male, mean age 62.7±9.9 years) were enrolled. We observed overtime, a significant reduction in estimated glomerular filtration rate (eGFR) (p=0.01), hemoglobin (Hb) (p=0.04) and 25-hydroxyvitamin D (25-OH-VitD) (p=0.002), in association with a significant increase in serum phosphorus (p
